[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospital Goettingen\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":107},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":24,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100574578","using-anonymous-data-from-a-digital-tool-for-medical-history-taking-to-improve-healthcare-services-100574578",false,"NCT06761105","Using Anonymous Data From A Digital Tool for Medical History-Taking To Improve Healthcare Services","Observation Of The Use Of Digital Tools for Medical History-Taking in Primary Care and Utilization of Anonymous Routine Data for Health Services Research","Inclusion Criteria:\n\n* all patients that use the app in a general practice that agreed to provide data\n* all ages (including children if the app is used by parent or legal guardian)\n* all complaints chosen in the app\n\nExclusion Criteria:\n\n* patients that use the app in a general practice that did not agree to provide data\n* patients that use the app in a general practice outside of the federal state Lower Saxony","ALL",{"count":18,"type":19},20,"ESTIMATED","OBSERVATIONAL","This study aims to understand how people use a mobile app that helps them record their symptoms before going to the doctor. Patients use the app on a tablet or other digital device. The app guides patients through a series of structured questions tailored to their symptoms. The data collected is then transferred to the practice's electronic record and is available to the treating doctor before and during the consultation.\n\nIn this project, anonymized usage data will be analyzed to contribute to the further development of the tool and to provide valuable insights for health services research.",[23],"Health Services Research",[25,26,27,28,29,30],"digital medical history","anonymized usage data","general practice","GP consultations","GP","health services research","RECRUITING","2026-04-30",{"date":34,"type":35},"2026-05-06","ACTUAL",{"date":37,"type":35},"2025-05-01",{"date":39,"type":19},"2033-12",{"name":41,"class":42},"University Hospital Goettingen","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":53,"targetDuration":55,"studyType":20,"phases":4,"briefSummary":56,"conditions":57,"keywords":63,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":43},"100238186","alport-therapy-registry---european-initiative-towards-delaying-renal-failure-in-alport-syndrome-100238186","NCT02378805","Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome","European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome: Current and Novel Therapies","Alport-XXL","Inclusion Criteria:\n\nDiagnosis of Alport syndrome (AS) by kidney biopsy or mutation analysis (or both).\n\nAny type of genetic variant is accepted for X-linked, autosomal or digenic Alport syndrome (COL4A3, 4 or 5 genes).\n\nExclusion criteria:\n\nPatients not willing to give informed consent. Patient with suspected diagnosis, whcih cannot be confirmed.",true,{"count":54,"type":19},800,"30 Years","The hereditary type IV collagen disease Alport syndrome leads to kidney failure early in life. Currently there are no specific medications approved for treatment, however, several therapies have been evaluated preclinically and could improve outcome. For that reason, this non-interventional, observational study investigates, if medications (1) delay disease progression; (2) delay time to kidney failure; (3) improve life-expectancy compared to untreated patients (relatives). This observational study started in 2006 as an European registry. Since 2019, this registry has been expanded to \"Alport XXL\" via the International Alport Alliance as a global effort across all continents. From 2020 on to present, \"Alport XXL\" has a special focus on the outcomes of early therapy in young patients on ACE-inhibitors vs. Angiotensin-receptor blockers vs. their combination.",[58,59,60,61,62],"Alport Syndrome","Hereditary Kidney Disease","Pediatric Kidney Disease","Thin Basement Membrane Disease","Familial Benign Hematuria",[64,65,66],"Alport syndrome","thin basement membrane disease","familial benign hematuria","2025-03-03",{"date":69,"type":35},"2025-03-06",{"date":71,"type":4},"1995-07",{"date":73,"type":19},"2036-03-01",{"name":41,"class":42},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},"100511790","phase-3-phase-3-clinical-trial-with-dapagliflozin-in-chronic-kidney-disease-in-adolescents-and-young-adult-patients-100511790","NCT05944016","Phase 3 Clinical Trial with Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients","DOUBLE PRO-TECT Alport: a Confirmatory, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Effect of Dapagliflozin on the Progression of Chronic Kidney Disease in Adolescents and Young Adult Patients with Alport Syndrome","DOUBLE_PROTECT","Key inclusion criteria:\n\nEarly stages of CKD with established diagnosis of Alport syndrome at visit 1 (screening)\n\n* adolescents ≥ 10 to \\\u003C 18 years with albuminuria (UACR ≥ 300mg\u002Fg creatinine) AND\n* eGFR ≥ 30 ml\u002Fmin\u002F1.73 m2 OR\n* adults ≥ 18 to \\\u003C 40 years with albuminuria (UACR ≥ 500mg\u002Fg creatinine) AND\n* eGFR ≥ 60 ml\u002Fmin\u002F1.73 m2\n\n  1. Molecular-genetic diagnosis or diagnosis established by kidney biopsy\n  2. Stable RAS blockade as background therapy.\n  3. Signed and dated written informed consent.\n\nKey exclusion criteria:\n\n1. Medical history that might limit the individual's ability to take trial treatments.\n2. Treatment with any SGLT2 inhibitor or within 4 weeks prior to Visit 1.\n3. eGFR\\\u003C60 mL\u002Fmin\u002F1.73 m2 (CKD-EPI) or requiring dialysis or after kidney-transplantation\n4. Uncontrolled arterial hypertension (blood pressure above 145\u002F95 mmHg).\n5. Known hypersensitivity or allergy to the investigational products.\n6. Any previous or current alcohol or drug abuse.\n7. Participation in another trial with an investigational drug ongoing.\n8. Women, who are nursing or pregnant, or who are not practicing an acceptable method of birth control.","10 Years","39 Years",{"count":86,"type":19},102,"INTERVENTIONAL",[89],"PHASE3","Recent trials have demonstrated positive renal outcomes of sodium-glucose co-transporter-2 inhibitors (SGLT2i) additive to angiotensin-converting-enzyme inhibitors (ACEis) in adult patients with diabetic and non-diabetic chronic kidney disease (CKD). These trials included no children. The hypothesis of DOUBLE PRO-TECT Alport is to demonstrate superiority of the SGLT2i dapagliflozin in preventing progression of the chronic kidney disease Alport syndrome in children and young adults at early stages of disease. Preventing the rise of albuminuria by dapagliflozin would result in a very significant delay of end-stage kidney failure (ESKF) and improved quality of life. If successful, DOUBLE PRO-TECT Alport will change the treatment recommendations for children with CKD, who have a very high unmet medical need.",[92],"Chronic Kidney Failure in Children and Young Adults",[94,95,96,64,97],"chronic kidney disease in children","pediatric population","nephroprotective therapy in children","type IV collagen disease","2024-12-11",{"date":100,"type":35},"2024-12-16",{"date":102,"type":35},"2024-03-25",{"date":104,"type":19},"2026-12",{"name":41,"class":42},16,""]